 Shengyu Mu
Concepts (186)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 10 | 2025 | 560 | 3.660 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2024 | 140 | 2.160 |
Why?
| | Interferon-gamma | 2 | 2024 | 169 | 0.930 |
Why?
| | Sodium | 3 | 2024 | 92 | 0.900 |
Why?
| | Molecular Targeted Therapy | 1 | 2025 | 135 | 0.870 |
Why?
| | Antihypertensive Agents | 1 | 2025 | 129 | 0.870 |
Why?
| | Blood Pressure | 3 | 2025 | 525 | 0.820 |
Why?
| | Kidney Tubules, Distal | 2 | 2022 | 14 | 0.710 |
Why?
| | KATP Channels | 1 | 2020 | 6 | 0.680 |
Why?
| | Kidney | 5 | 2024 | 716 | 0.670 |
Why?
| | Lymphatic Vessels | 1 | 2020 | 38 | 0.650 |
Why?
| | Muscle Contraction | 1 | 2020 | 109 | 0.650 |
Why?
| | Edema | 1 | 2020 | 63 | 0.640 |
Why?
| | Epithelial Cells | 2 | 2022 | 217 | 0.630 |
Why?
| | Sodium Chloride, Dietary | 5 | 2024 | 33 | 0.600 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2024 | 570 | 0.530 |
Why?
| | Animals | 19 | 2025 | 13485 | 0.510 |
Why?
| | Mice, Knockout | 6 | 2024 | 903 | 0.510 |
Why?
| | Cocaine | 1 | 2018 | 168 | 0.510 |
Why?
| | Mice, Inbred C57BL | 5 | 2024 | 1888 | 0.460 |
Why?
| | Mice | 12 | 2024 | 5899 | 0.440 |
Why?
| | T-Lymphocytes | 2 | 2025 | 318 | 0.380 |
Why?
| | Sarcoma, Kaposi | 2 | 2023 | 76 | 0.370 |
Why?
| | Herpesvirus 8, Human | 2 | 2023 | 97 | 0.360 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2011 | 16 | 0.350 |
Why?
| | Inflammation | 3 | 2025 | 649 | 0.340 |
Why?
| | Cannabinoids | 2 | 2022 | 103 | 0.330 |
Why?
| | Rats | 6 | 2024 | 3228 | 0.310 |
Why?
| | Reactive Oxygen Species | 5 | 2020 | 415 | 0.310 |
Why?
| | Sodium Chloride Symporters | 2 | 2022 | 6 | 0.280 |
Why?
| | Rats, Sprague-Dawley | 5 | 2024 | 1558 | 0.270 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2020 | 95 | 0.260 |
Why?
| | Disease Models, Animal | 6 | 2024 | 1483 | 0.260 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2020 | 135 | 0.250 |
Why?
| | Adenosine Triphosphate | 2 | 2024 | 234 | 0.240 |
Why?
| | Fibrosis | 2 | 2024 | 198 | 0.230 |
Why?
| | Oxidative Stress | 4 | 2015 | 805 | 0.220 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2024 | 4 | 0.220 |
Why?
| | Lymphangiogenesis | 1 | 2024 | 5 | 0.220 |
Why?
| | Receptors, Purinergic P2X7 | 1 | 2024 | 6 | 0.210 |
Why?
| | Histone Deacetylases | 1 | 2024 | 50 | 0.210 |
Why?
| | Signal Transduction | 6 | 2022 | 1724 | 0.210 |
Why?
| | Endothelial Cells | 2 | 2024 | 283 | 0.210 |
Why?
| | Ureteral Obstruction | 1 | 2024 | 62 | 0.200 |
Why?
| | Echinomycin | 1 | 2023 | 6 | 0.200 |
Why?
| | Atherosclerosis | 2 | 2020 | 224 | 0.190 |
Why?
| | Ion Channels | 1 | 2023 | 74 | 0.190 |
Why?
| | Protons | 1 | 2023 | 74 | 0.190 |
Why?
| | Cells, Cultured | 3 | 2020 | 1583 | 0.180 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2022 | 29 | 0.180 |
Why?
| | rac1 GTP-Binding Protein | 2 | 2011 | 11 | 0.180 |
Why?
| | Benzoxazines | 1 | 2021 | 18 | 0.180 |
Why?
| | Sarcoma, Ewing | 1 | 2021 | 31 | 0.180 |
Why?
| | Morpholines | 1 | 2021 | 64 | 0.180 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2021 | 57 | 0.170 |
Why?
| | Cromakalim | 1 | 2020 | 4 | 0.170 |
Why?
| | Minoxidil | 1 | 2020 | 5 | 0.170 |
Why?
| | Diazoxide | 1 | 2020 | 7 | 0.170 |
Why?
| | Potassium | 1 | 2020 | 54 | 0.170 |
Why?
| | Receptors, Mineralocorticoid | 3 | 2024 | 12 | 0.170 |
Why?
| | Naphthalenes | 1 | 2021 | 120 | 0.170 |
Why?
| | Humans | 11 | 2025 | 52441 | 0.170 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2021 | 123 | 0.160 |
Why?
| | Action Potentials | 1 | 2020 | 128 | 0.160 |
Why?
| | TRPM Cation Channels | 1 | 2019 | 4 | 0.160 |
Why?
| | TRPC Cation Channels | 1 | 2020 | 15 | 0.160 |
Why?
| | Interleukin-1beta | 1 | 2020 | 84 | 0.160 |
Why?
| | Cytokines | 1 | 2022 | 622 | 0.160 |
Why?
| | Inflammasomes | 1 | 2020 | 64 | 0.150 |
Why?
| | Status Epilepticus | 1 | 2020 | 34 | 0.150 |
Why?
| | Macrophages | 1 | 2022 | 357 | 0.150 |
Why?
| | Carotid Body | 1 | 2019 | 43 | 0.150 |
Why?
| | Male | 11 | 2024 | 26874 | 0.150 |
Why?
| | Prostatic Neoplasms | 1 | 2022 | 398 | 0.140 |
Why?
| | Malate Dehydrogenase | 1 | 2018 | 8 | 0.140 |
Why?
| | Vascular Stiffness | 1 | 2018 | 24 | 0.140 |
Why?
| | Diet, High-Fat | 2 | 2020 | 230 | 0.130 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2017 | 7 | 0.130 |
Why?
| | Deoxycholic Acid | 1 | 2017 | 17 | 0.130 |
Why?
| | Ion Transport | 1 | 2017 | 16 | 0.130 |
Why?
| | Chloride Channels | 1 | 2017 | 26 | 0.130 |
Why?
| | Adoptive Transfer | 1 | 2017 | 30 | 0.130 |
Why?
| | Chlorides | 1 | 2017 | 49 | 0.130 |
Why?
| | Coculture Techniques | 1 | 2017 | 142 | 0.130 |
Why?
| | src-Family Kinases | 1 | 2017 | 50 | 0.130 |
Why?
| | Lung Neoplasms | 1 | 2022 | 643 | 0.120 |
Why?
| | Dyslipidemias | 1 | 2015 | 42 | 0.110 |
Why?
| | Sodium, Dietary | 1 | 2015 | 24 | 0.110 |
Why?
| | Scavenger Receptors, Class E | 2 | 2015 | 200 | 0.110 |
Why?
| | Rats, Inbred Dahl | 2 | 2011 | 11 | 0.110 |
Why?
| | MicroRNAs | 1 | 2018 | 392 | 0.100 |
Why?
| | Glucuronidase | 1 | 2013 | 47 | 0.100 |
Why?
| | Vascular Calcification | 1 | 2013 | 21 | 0.100 |
Why?
| | Phosphates | 1 | 2013 | 51 | 0.100 |
Why?
| | Fatty Liver | 1 | 2015 | 141 | 0.100 |
Why?
| | Fibroblast Growth Factors | 1 | 2013 | 48 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 1216 | 0.100 |
Why?
| | Aortic Diseases | 1 | 2013 | 54 | 0.100 |
Why?
| | Gene Expression Regulation | 1 | 2017 | 1004 | 0.090 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 102 | 0.090 |
Why?
| | Pulmonary Artery | 1 | 2013 | 142 | 0.090 |
Why?
| | CA1 Region, Hippocampal | 1 | 2011 | 21 | 0.090 |
Why?
| | Lipoproteins, LDL | 1 | 2013 | 177 | 0.090 |
Why?
| | Models, Biological | 2 | 2011 | 735 | 0.090 |
Why?
| | Blood Preservation | 1 | 2011 | 27 | 0.090 |
Why?
| | Receptors, Glucocorticoid | 1 | 2011 | 35 | 0.090 |
Why?
| | DNA Primers | 1 | 2011 | 204 | 0.090 |
Why?
| | RNA, Small Interfering | 1 | 2011 | 217 | 0.080 |
Why?
| | Base Sequence | 1 | 2011 | 632 | 0.080 |
Why?
| | Mice, Transgenic | 3 | 2020 | 566 | 0.080 |
Why?
| | Histones | 1 | 2011 | 315 | 0.070 |
Why?
| | Epigenesis, Genetic | 1 | 2011 | 396 | 0.070 |
Why?
| | MAP Kinase Signaling System | 2 | 2020 | 128 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2024 | 3 | 0.050 |
Why?
| | Spironolactone | 1 | 2024 | 4 | 0.050 |
Why?
| | Phagocytosis | 1 | 2024 | 54 | 0.050 |
Why?
| | Myeloid Cells | 1 | 2024 | 42 | 0.050 |
Why?
| | Retina | 1 | 2024 | 60 | 0.050 |
Why?
| | Myofibroblasts | 1 | 2024 | 50 | 0.050 |
Why?
| | Reperfusion Injury | 1 | 2024 | 73 | 0.050 |
Why?
| | Retinal Diseases | 1 | 2024 | 53 | 0.050 |
Why?
| | Receptors, Histamine | 1 | 2023 | 6 | 0.050 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2023 | 18 | 0.050 |
Why?
| | Histamine | 1 | 2023 | 24 | 0.050 |
Why?
| | Virus Latency | 1 | 2023 | 53 | 0.050 |
Why?
| | Mitochondrial Proteins | 1 | 2023 | 91 | 0.050 |
Why?
| | Tubercidin | 1 | 2022 | 3 | 0.050 |
Why?
| | Amaryllidaceae Alkaloids | 1 | 2022 | 3 | 0.050 |
Why?
| | Phenanthridines | 1 | 2022 | 4 | 0.050 |
Why?
| | Transaminases | 1 | 2022 | 12 | 0.050 |
Why?
| | Receptors, Cannabinoid | 1 | 2022 | 18 | 0.050 |
Why?
| | Cell Cycle | 1 | 2023 | 236 | 0.050 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2023 | 187 | 0.050 |
Why?
| | Cytotoxins | 1 | 2021 | 15 | 0.050 |
Why?
| | Binding, Competitive | 1 | 2021 | 92 | 0.040 |
Why?
| | Cell Death | 1 | 2022 | 169 | 0.040 |
Why?
| | Prostate | 1 | 2022 | 116 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 205 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2022 | 263 | 0.040 |
Why?
| | Enzyme Inhibitors | 2 | 2013 | 378 | 0.040 |
Why?
| | Macrophages, Peritoneal | 1 | 2020 | 30 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2020 | 63 | 0.040 |
Why?
| | Pentylenetetrazole | 1 | 2020 | 9 | 0.040 |
Why?
| | Immunotherapy | 1 | 2022 | 251 | 0.040 |
Why?
| | Pilocarpine | 1 | 2020 | 20 | 0.040 |
Why?
| | Mitochondria | 1 | 2023 | 420 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2020 | 126 | 0.040 |
Why?
| | Leptin | 1 | 2019 | 148 | 0.040 |
Why?
| | Electroencephalography | 1 | 2020 | 301 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2021 | 1429 | 0.030 |
Why?
| | NADP | 1 | 2015 | 22 | 0.030 |
Why?
| | Superoxides | 1 | 2015 | 46 | 0.030 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2013 | 9 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 580 | 0.030 |
Why?
| | Blotting, Western | 1 | 2015 | 587 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2013 | 12 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 83 | 0.030 |
Why?
| | Ventricular Pressure | 1 | 2013 | 16 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2013 | 269 | 0.020 |
Why?
| | Tyrosine | 1 | 2013 | 97 | 0.020 |
Why?
| | Ventricular Function, Right | 1 | 2013 | 40 | 0.020 |
Why?
| | Transfection | 1 | 2013 | 365 | 0.020 |
Why?
| | Sympathetic Nervous System | 1 | 2012 | 18 | 0.020 |
Why?
| | Aorta | 1 | 2013 | 170 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2013 | 490 | 0.020 |
Why?
| | Phosphorylation | 1 | 2013 | 536 | 0.020 |
Why?
| | Acetophenones | 1 | 2011 | 12 | 0.020 |
Why?
| | Corticosterone | 1 | 2011 | 19 | 0.020 |
Why?
| | Aminoquinolines | 1 | 2011 | 8 | 0.020 |
Why?
| | Excitatory Postsynaptic Potentials | 1 | 2011 | 30 | 0.020 |
Why?
| | Aldosterone | 1 | 2011 | 5 | 0.020 |
Why?
| | Brain | 1 | 2020 | 1337 | 0.020 |
Why?
| | Up-Regulation | 1 | 2013 | 462 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 231 | 0.020 |
Why?
| | Proteinuria | 1 | 2011 | 40 | 0.020 |
Why?
| | Antioxidants | 1 | 2013 | 255 | 0.020 |
Why?
| | Obesity | 1 | 2019 | 1176 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 667 | 0.020 |
Why?
| | Chronic Disease | 1 | 2013 | 579 | 0.020 |
Why?
| | Osteoblasts | 1 | 2013 | 478 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2013 | 198 | 0.020 |
Why?
| | Pyrimidines | 1 | 2011 | 199 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 1365 | 0.020 |
Why?
| | Disease Progression | 1 | 2013 | 870 | 0.020 |
Why?
| | Liver | 1 | 2015 | 1150 | 0.020 |
Why?
| | Kidney Diseases | 1 | 2011 | 230 | 0.020 |
Why?
|
|
Mu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|